乳腺浸润性导管癌病灶与腋窝转移淋巴结中ER和HER-2表达的关系

目的：探讨雌激素受体（ER）和人表皮生长因子受体（HER-2）在人乳腺浸润性导管癌肿瘤病灶与腋窝转移淋巴结中表达的关系。 方法：检测80例乳腺癌肿瘤病灶和转移淋巴结中ER（免疫组化法）和HER-2（荧光原位杂交法）的表达情况,并分析两者相关性与一致性。 结果：80例患者中,乳腺癌肿瘤病灶ER阳性34例（42.50%）,HER-2阳性26例（32.50%）;腋窝淋巴结转移灶ER阳性37例（46.25%）,HER-2阳性27例（33.75%）,两者在肿瘤病灶与腋窝淋巴结的阳性率差异均无统计学意义（P=0.750,P=1.000）。肿瘤病灶与腋窝转移淋巴结ER均阳性32例,HER-2均阳性22例,肿瘤病灶与腋窝转移淋巴结两种受体表达情况总符合率为83.75%,两者在原发灶与腋窝淋巴结转移灶的表达具有较好的相关性和一致性（r=0.825,0.746;κ=0.823,0.764）。 结论：人乳腺浸润性导管癌肿瘤病灶与腋窝转移淋巴结中ER和HER-2表达具有较好的相关性与一致性。     

乳腺癌中c-erbB-2和nm23蛋白的表达及其临床病理意义

目的研究c-erbB-2和nm23基因蛋白在乳腺癌中的表达及其临床病理意义。方法应用免疫组化SP法,检测107例乳腺癌c-erbB-2及nm23基因蛋白的表达,同时检测ER和PR。结果 (1)c-erbB-2在浸润性导管癌中呈高表达;nm23在浸润性小叶癌中呈高表达。(2)c-erbB-2表达与组织学分级、TNM临床分期及与有无腋窝淋巴结转移之间有统计学差异,而与患者的年龄、肿瘤体积c-erbB-2,nm23表达无相关性。(3)nm23表达与TNM临床分期及有无腋窝淋巴结转移有关,该两指标分组间差异有统计学意义,而与患者的年龄、肿瘤体积、组织学分级c-erbB-2,nm23表达无关。(4)c-erbB-2和nm23蛋白表达无关。结论 ER,PR,c-erbB-2及nm23的联合检测能较好地反映乳腺癌病理生物学特征。     

乳腺癌原发灶及淋巴结转移灶中表皮生长因子受体、C-erbB-2的表达及临床意义

目的 探讨乳腺癌原发灶和淋巴结转移灶中表皮生长因子受体（EGFR）、C-erbB-2的表达及其与肿瘤类型、肿瘤分期的关系.方法 选择行手术治疗且术前均未行抗癌治疗,术后病理证实无同侧腋窝淋巴结转移的乳腺癌患者24例,伴有同侧腋窝淋巴结转移的乳腺癌患者36例,用免疫组化S-P法检测原发灶和淋巴结转移灶EGFR、C-erbB-2的表达.结果 有同侧腋窝淋巴结转移的乳腺癌原发灶EGFR、C-erbB-2的表达明显高于无同侧腋窝淋巴结转移的乳腺癌.乳腺癌原发灶EGFR、C-erbB-2的表达呈正相关（P=0.01）.原发灶和淋巴结转移灶之间的EGFR、C-erbB-2的表达无相关性.原发灶EGFR、C-erbB-2的表达在不同的肿瘤分期存在差异.浸润性导管癌和浸润性小叶癌之间EGFR、C-erbB-2的表达无差异.结论 乳腺癌细胞淋巴结转移的过程中由于体内某种机制的作用导致了恶性程度的变化;EGFR、C-erbB-2的表达正相关并共同促进了乳腺癌的淋巴结转移;原发灶EGFR、C-erbB-2的表达与肿瘤的分期呈正相关.     

端粒酶逆转录酶、环氧化酶-2在乳腺癌中的表达及其意义

目的 探讨端粒酶逆转录酶(hTERT)和环氧化酶(cox)-2在乳腺浸润性导管癌中的表达及其临床意义.方法 使用免疫组织化学法分别检测45例乳腺浸润性导管癌和22例乳腺良性病变标本的hTERT和COX-2蛋白表达情况.结果 hTERT在乳腺浸润性导管癌中阳性表达率fig71.11%,明显高于乳腺良性病变9.09%,两者比较差异有统计学意义(P<0.05).hTERT阳性表达与乳腺浸润性导管癌患者的年龄、肿瘤大小、腋窝淋巴结转移情况及雌、孕激素表达水平无相关性(P>0.05),与Her-2表达存在显著相关性(P<0.05).COX-2在乳腺浸润性导管癌中的阳性表达率为82.22%,明显高于乳腺良性病变50.00%,两者比较差异有统计学意义(P<0.05).COX-2阳性表达与乳腺浸润性导管癌患者腋窝淋巴结转移情况、Her-2、ER阳性表达有关(P<0.05).在乳腺浸润性导管癌中hTERT阳性表达与COX-2阳性表达呈正相关(r=0.557,P<0.01).结论 hTERT与COX-2在乳腺浸润性导管癌中的表达显著高于在乳腺良性病变中的表达,hTERT与COX-2在乳腺癌的发生、发展中起重要作用.hTERT表达与COX-2表达存在显著相关性,COX-2的过度表达可能是端粒酶激活和调节的机制之一.     

Slit2在乳腺组织的表达与乳腺癌脑转移的关系

目的 检测神经轴突导向蛋白2(Slit2)在不同乳腺肿瘤组织中的表达,探讨Slit2与乳腺癌脑转移的相关性.方法 采用免疫组织化学LSAB法检测对24例发生脑转移的乳腺浸润性导管癌(IDC)、71例未发生脑转移的乳腺浸润性导管癌、22例乳腺导管内癌和23例乳腺腺纤维瘤组织中Slit2的表达.结果 Slit2在浸润性导管癌中有脑转移患者的阳性表达率(13%)明显低于无脑转移患者(59%)(P＜0.05);在乳腺导管内癌和浸润性导管癌中的阳性表达率(59%和48%)均明显低于乳腺纤维瘤(87%,P＜0.05);但前两者间差异无统计学意义(P＞0.05);在50岁以上乳腺癌患者中的阳性表达率(62%)明显高于50岁及以下患者(34%,P＜0.05);在生存期＜5年的乳腺浸润性导管癌患者组织中Slit2的阳性表达率(18%)明显低于生存期＞5年的患者(59%)(P＜0.05).Slit2阴性的患者总生存时间明显短于Slit2阳性患者(P＜0.01).Slit2在乳腺癌中的表达与肿瘤大小、淋巴结转移状态、病理学分期、组织学分级均无明显相关(P＞0.05).结论 乳腺癌中Slit2的表达和乳腺癌脑转移呈负相关,和乳腺浸润性导管癌患者的发病年龄及预后呈正相关,可成为判断乳腺癌预后和脑转移的分子标志物.     

CD24在乳腺浸润性导管癌中的表达及临床意义

目的:研究CD24在乳腺浸润性导管癌组织不同模式中的表达及其与临床病理因素的相关性。方法:用SP免疫组化染色法检测13例乳腺纤维腺瘤及46例乳腺浸润性导管癌组织中CD24的表达。结果: 浸润性乳腺导管癌组织中CD24在细胞膜和细胞浆都有表达，阳性率为80.43%；乳腺纤维腺瘤CD24仅在细胞膜上局灶性表达，阳性率为53.85%。CD24在浸润性导管癌中的表达浓度明显高于纤维腺瘤(P＜0.05)；并与腋窝淋巴结转移正相关(P＜0.05)；CD24细胞膜表达与雌、孕激素受体阳性表达密切相关(P＜0.001)，而与患者年龄、肿瘤大小、肿瘤分期、分级、Her 2及p53等因素无相关性（P＞0.05）。结论:CD24高表达参与乳腺癌的侵袭与转移，CD24细胞膜表达可能与乳腺癌内分泌治疗抵抗作用相关，CD24可作为乳腺不良预后的判断指标之一。     

乳腺浸润性导管癌组织中PTTG及COX2的表达及临床意义

目的:检测乳腺浸润性导管癌组织中垂体肿瘤转化基因(pituitary tumor-transforming gene,PTTG)和环氧化酶2(cyclooxygenase-2,COX2)的蛋白表达水平并分析与其他临床病理特征的关系。方法:用免疫组织化学Evinson法检测104例乳腺浸润性导管癌组织中PTTG和COX2的蛋白表达水平。结果:104例乳腺浸润性导管癌组织中,有95例检测到PTTG阳性表达,阳性率为91%,其中41例呈低表达(39%),54例呈高表达(52%)。104例乳腺浸润性导管癌组织中,有70例检测到COX2阳性表达,阳性率为67%,其中53例呈低表达(51%),17例呈高表达(16%);PTTG表达与肿瘤大小、组织学分级密切相关,组织学分级越高,PTTG表达越强,PTTG表达与年龄、淋巴结转移、ER、PR和HER2状态无关;COX2表达与ER表达、肿瘤大小、组织学分级和淋巴结转移相关,ER( )组的COX2表达高于ER(-)组,COX2表达与PTTG表达、年龄、PR和HER2状态无关。结论:PTTG和COX2在乳腺浸润性导管癌组织中的表达可能促进乳腺浸润性导管癌的发生发展,并且与低分化、预后不良有关。COX2可能通过刺激雌激素合成来促进乳腺癌细胞增殖。COX2可能促进乳腺癌侵袭转移。     

P53、bcl-2及c-erbB-2蛋白在乳腺浸润性导管癌组织的表达及意义

目的:观察乳腺浸润性导管癌组织内P53、bcl-2及c-erbB-2蛋白表达,并分析其临床意义。方法:选取2016年12月—2017年10月接受治疗的乳腺浸润性导管癌患者为研究对象,选取同期接受治疗的乳腺良性肿瘤患者作为对照。观察两组研究对象和乳腺浸润性导管癌患者肿瘤组织中P53、bcl-2及c-erbB-2蛋白阳性表达情况,并分析其影响因素。结果:乳腺癌组患者P53、c-erbB-2阳性表达率高于对照组,bcl-2阳性表达率低于对照组(P0.05);P53、c-erbB-2及bcl-2的表达与分化程度、有无淋巴结转移、浸润深度、TNM分期有关(P0.05);与患者年龄无关(P0.05);以单因素分析有意义的因素作为自变量,将乳腺癌患者P53、bcl-2及c-erbB-2阳性表达情况作为因变量进行回归分析,结果显示分化程度和TNM分期是影响P53、bcl-2及c-erbB-2阳性表达的因素。结论:乳腺浸润性导管癌患者组织内P53、c-erbB-2蛋白阳性表达率较高,bcl-2阳性表达率较低,且与分化程度和TNM分期密切有关。     

乳腺浸润性导管癌分子亚型与腋窝淋巴结转移的关系

目的:探讨乳腺浸润性导管癌不同分子亚型与其腋窝淋巴结转移的关系。方法:根据乳腺癌分子分型标准,将243例原发乳腺浸润性导管癌的手术患者分为Luminal A型、Luminal B型[又分为HER-2(-)和HER-2(+)]、HER-2过表达型和三阴型。结合临床病理资料,分析各分子亚型的分布特点,以及与腋窝淋巴结转移的关系。结果:243例患者中,Luminal B[HER-2(-)]型最多(78例,32.1%),其次是Luminal A型(58例,23.87%),随后为三阴型(41例,16.87%)、HER-2过表达型(34例,13.99%)、Luminal B[HER-2(+)]型(32例,13.17%);94例(38.68%)发生腋窝淋巴结转移,各分子亚型患者腋窝淋巴结转移发生率差异有统计学意义(P0.05),其中Luminal B[HER-2(-)]型(42例,53.85%)和Luminal B[HER-2(+)]型(15例,46.88%)中发生率最高,且两者间差异无统计学意义(P0.05),其后依次为Luminal A型(19例,32.76%),三阴型(12例,29.27%),HER-2过表达型(6例,17.65%);各分子亚型分布在累及1~3枚及≥4枚淋巴结转移的分组中,差异均无统计学意义(均P0.05),但前者Luminal B[HER-2(+)]型最多,HER-2过表达型最少,而后者HER-2过表达型最多,Luminal B[HER-2(+)]型最少。结论:乳腺浸润性导管癌的分子分型对评估腋窝淋巴结转移状况、判断疾病状态有一定参考价值,可成为制定个体化诊治策略的依据。     

乳腺癌中细胞周期素D1基因改变和转录异常对其蛋白表达的影响

目的:研究乳腺癌中细胞周期素D1(cyclin D1)在DNA、mRNA和蛋白水平的改变,探讨cyclinD1基因改变和转录异常对其蛋白表达的影响.方法:免疫组织化学检测cyclin D1蛋白表达,RT-PCR检测cyclin D1 mRNA的转录异常, southern杂交检测cyclin Dl的基因改变.结果:(1)yclin D1蛋白在乳腺癌中表达阳性率为54%.(2)cyclin D1在早期乳腺癌、浸润性导管癌原发灶、腋窝淋巴结转移灶中表达阳性率的差异无统计学意义.(3)浸润性导管癌中15%出现cydinDl基因扩增,35%出现cyc-lin D1 mRNA表达升高.结论:(1)cyclin D1蛋白表达是乳腺癌发生中的早期事件,且在乳腺癌进程中有稳定保持的趋势.(2)cyclin D1的蛋白表达除受基因扩增和mRNA表达升高的影响外,还受到其他因素的影响.     

乳腺癌c-erbB-2与雌孕激素受体及淋巴结转移的相关性分析

目的：分析乳腺癌c-erbB-2的表达与ER、PR，以及腋窝淋巴结、肿瘤大小、病理类型的相关性。方法：收集术前未行新辅助化疗而行手术切除加腋窝清扫的乳腺癌病人346例，采用免疫组化法检测c-erbB-2、ER及PR；比较c-erbB-2表达与ER、PR、腋窝淋巴结、肿瘤大小以及病理类型之间的关系。结果：c-erbB-2阳性表达者占48．2％，腋窝淋巴结有转移者的c-erbB-2阳性表达为69．6％，而淋巴结阴性者则为34．6％（P〈0．001）。ER、PR均阳性且c-erbB-2表达也阳性者为38．1％；而ER、PR均阴性、c-erbB-2阳性者达64．6％（P〈0．001）。仅ER阳性和阴性者的c-erbB-2阳性表达分别是40．7％和69.2％（P（0．001）。仅PR阳性和阴性者的c-erbB-2阳性分别为46．4％和49．7％（P〉0．05）。〈2cm和2～5cm肿瘤的c-erbB-2阳性率分别是47．1％和48．8％（P〉0．05）。导管内癌和黏液癌的c-erbB-2表达阳性率分别达73．8％和60．0％。结论：c-erbB-2阳性表达与腋窝淋巴结的转移呈正相关，与ER呈负相关，与PR和肿瘤大小不相关。c-erbB-2是判断乳腺癌预后的良好指标。     

表皮生长因子受体家族EGFR、c-erbB-2和c-erbB-3在大肠肿瘤中的表达

目的:探讨表皮生长因子受体家族EGFR、c-erbB-2和c-erbB-3三种蛋白的共同表达与大肠良恶性肿瘤的关系。方法:选取病理检查证实的大肠息肉、大肠腺瘤和大肠腺癌共151例,采用免疫组化ENVISION技术分别对所选取的标本进行EGFR、c-erbB-2和c-erbB-3检测,并对结果进行统计学分析。结果:增生性息肉组EGFR、c-erbB-2和c-erbB-3三者单一表达或三者均不表达的比率较高(42.86％和35.71％),二者和三者共同表达的比率低(19.05％和2.38％);腺瘤与腺癌组均出现较高的二者和三者同时表达的比率,而三者共同表达在腺癌组中的比率明显高于息肉组和腺瘤组(P<0.01)。大肠息肉中,c-erbB-2单一表达率较高(28.57％) ;腺瘤和腺癌中分别有一种蛋白不出现单一表达,为c-erbB-3和c-erbB-2;在大肠息肉和腺瘤中,均未出现有c-erbB-3与EGFR的共同表达。结论:在不同类型的大肠肿瘤中,EGFR家族蛋白的表达或共同表达具有不同特点;在大肠癌的发生发展中,三种蛋白在信号传导过程中呈共同表达。     

原癌基因在乳腺癌中的表达及其与预后关系的研究

目的检测原癌基因（c-erbB-2）在乳腺癌中的表达及探讨与乳腺癌预后的关系。方法采用免疫组织化学法对癌基因进行标定，检测40例乳腺癌中c-erbB-2的表达。结果浸润性乳腺癌中c-erbB-2阳性表达率明显高于原位癌（P〈0．01）；c-erbB-2阴性组10年的总存活率（100％）高于阳性组（86．1％）。结论c-erbB-2对于反映乳腺癌细胞侵袭力及判断预后具有重要意义。     

在分子生物学水平上对膀胱癌的发生与治疗进行深入的研究

在分子生物学水平上对膀胱癌的发生与治疗进行深入的研究马腾骧Ａｍｏｌｅｃｕｌａｒｐａｔｈｏｌｏｇｉｃａｌｓｔｕｄｙｏｆｔｈｅｃａｒｃｉｎｏｇｅｎｅｓｉｓｏｆｔｒａｎｓｉｔｉｏｎａｌｅｐｉｔｈｅｌｉｕｍｂｌａｄｄｅｒｃａｎｃｅｒ￥ＣｈａｎｇＪｉ－ｗｕ；Ｍ...     

胆囊癌组织CD15和c-erbB-2表达及相关性研究

目的: 研究CD15抗原和c-erbB-2癌基因蛋白产物在胆囊癌组织中的表达与组织类型、病理分级和转移的关系,并探讨CD15与癌基因蛋白表达的相关性。方法: 应用微波-SP免疫组化法,检测45例胆囊腺癌、17例胆囊腺瘤和10例慢性胆囊炎组织中CD15和c-erbB-2的表达水平。结果: 在胆囊癌中CD15和c-erbB--2阳性表达率分别为71.1％和48.9％。其表达阳性率在胆率癌中均明显高于胆囊腺瘤(P<0.05),并与胆囊癌的类型、病理分级和转移密切相关(P<0.05)。CD15表达与c-erbB-2表达呈明显相关联。结论: CD15和c-erbB-2是胆囊癌高度恶性和预后不良重要生物学指标。胆囊癌CD15表达与c-erbB-2蛋白表达具有相互协同作用可能。     

Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) and c-erbB-2 are 2 of the 4 members of the erbB receptor family that play a role in signaling by forming heterodimers between family members. METHODS: The immunohistochemical expression of EGFR and c-erbB-2 was determined on 670 women who underwent operation for primary breast cancer. RESULTS: According to the combination of EGFR and c-erbB-2, 670 patients were classified into 4 groups: EGFR(-)/c-erbB-2(-) (417 patients); EGFR(+)/c-erbB-2(-) (136 patients); EGFR(-)/c-erbB-2(+) (72 patients); and EGFR(+)/c-erbB-2(+) (45 patients). Univariate analyses on disease-free and overall survival showed a significant difference among these 4 groups, whereas the difference between patients with positive and negative expression of EGFR was not statistically significant in patients with positive expression of c-erbB-2. A multivariate analysis indicated the combination of EGFR and c-erbB-2 to be an independently significant prognostic factor for disease-free and overall survival. CONCLUSIONS: Breast cancer with both a positive EGFR and c-erbB-2 expression had the worst prognosis, whereas the prognostic value of c-erbB-2 was stronger than that of EGFR in breast cancer.     

Lymphovascular and marginal invasion as useful prognostic indicators and the role of c-erbB-2 in patients with male extramammary Paget's disease: a study of 31 patients

PURPOSE: Extramammary Paget's disease (EMPD) is a rare intraepithelial neoplasm arising in skin that bears apocrine glands. We analyzed clinical, pathological and immunohistochemical staining patterns in 31 cases of EMPD to assess possible predictors of outcome, including patient age, sex, involved organs, surgical margin status, invasion depth, lymphovascular invasion, adnexal invasion, and immunoreactivity for cytokeratin 7 and 20, carcinoembryonic androgen, androgen receptor, p53, c-erbB-2 (Dako, Carpinteria, California) and Ki67. MATERIALS AND METHODS: A total of 31 cases of EMPD were retrieved from the surgical pathology files of the department of pathology along with the medical records of the department of urology. Dermal invasion depth, tumor margin status, adnexal invasion and lymphovascular invasion were determined from the hematoxylin and eosin stained slides of each case. RESULTS: Eight of the 31 cases (25.8%) experienced local recurrence. Two of 3 patients with and 6 of 28 without lymphovascular invasion experienced recurrence (p = 0.029). Dermal invasion significantly correlated with Her-2 over expression (Wilcoxon 2-sample test p = 0.0007). When the criteria of 1 and 5 mm invasion were applied, each validly correlated with Her-2 over expression. Her-2 over expression (grades 2 and 3) significantly correlated with p53 over expression (Wilcoxon rank test p = 0.0015). C-erbB-2 was positive in 51.6% of EMPD cases, in which it was strongly associated with dermal invasion and p53 over expression. CONCLUSIONS: The most valid prognostic factor in male EMPD for predicting late recurrence is lymphovascular permeation and marginal status.     

散发性乳腺癌BRCA1基因的表达及其临床意义

目的　探讨BRCA1基因蛋白在汉族散发性乳腺癌中的表达及其临床病理意义。方法　采用免疫组化SP法对 5 1例乳腺癌石蜡切片组织进行BRCA1检测 ,并分析它与临床病理指标及c erbB 2表达的关系。　结果　BRCA1蛋白定位于癌细胞核 ,其失表达和低表达率为 49%。BRCA1蛋白表达下调与c erbB 2表达相关 (tr=4 15 5 ,P <0 0 5 ) ,与组织学分级、肿块大小、淋巴结转移数目及患者年龄均无明显相关。　结论　BRCA1蛋白表达的检测可在一定程度上反映基因的改变 ,可作为乳腺癌易感性初筛的手段。     

Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands.

BACKGROUND: Adenoid cystic carcinoma (ACC) of the salivary gland shows a variable clinical course. It would be helpful to discover reliable biologic markers in the management of patients with ACC. METHODS: We examined proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein expression on 30 cases of ACC of the salivary glands. The immunohistochemical results, and size, location, and histologic grade of the tumors were compared with the clinical outcome of the patients. RESULTS: Mean PCNA positivity of ACCs was 15%, and was higher in solid than in cribriform/tubular areas. High PCNA value was significantly correlated with shorter disease-free and overall survival of the patients with ACC. c-erbB-2 overexpression was observed in only five cases, focally in cribriform/tubular areas. High histologic grade, which was determined by the presence of solid components, showed a trend toward shorter survival. Size and location of ACC were not associated with patient outcome. CONCLUSIONS: The present study indicates that PCNA score may be one of the most useful prognostic factor of ACC.     

DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma--in relation to clinicopathologic findings and prognosis

The nuclear DNA ploidy pattern and c-erbB-2 oncoprotein expression in primary and metastatic lesions were investigated using paraffin-embedded materials from 44 cases of colorectal carcinoma with hepatic metastases and 45 cases without hepatic metastases. The frequency of aneuploidy and positive staining of c-erbB-2 in primary tumor with hepatic metastases were significantly higher compared with those without hepatic metastases (p less than 0.05). There were significant correlations between diameter of metastases and DNA ploidy pattern of the metastases and between metachronous metastases, degree of metastases, vessel involvement and DNA ploidy pattern of the primary tumor. Positive staining of c-erbB-2 was detected more frequently with the advancement of depth of tumor invasion. There was no significant correlation between DNA ploidy pattern and c-erbB-2 expression. In the survival of patients whose primary tumor and hepatic metastases were resected, it was shown that DNA ploidy pattern of metastases was the most important independent prognostic factor. Expression of c-erbB-2 in primary tumor predicted the hepatic metastases.